INmune Bio, Inc.
XPro1595
Alzheimer's disease
Resolved
54days ago
FDA decision · May 14, 2026
What's at stake
The FDA's approval decision on XPro1595 for Alzheimer's disease is due May 14, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“the recent grant of FDA Fast Track designation for XPro™ in early Alzheimer’s disease.”